Apontis Pharma AG (FRA:APPH) Quality Rank


FRA:APPH Apontis Pharma AG FRA:APPH
17 GF Score
Price €11.00
GF Value €10.46
! 7 Warning Signs
View Full Analysis

What is Apontis Pharma AG Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Apontis Pharma AG Quality Rank Related Terms

FRA:APPH
17GF Score
Apontis Pharma AG FRA:APPH
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?

Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued. The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.

Key valuation signals for FRA:APPH:

  • Quality Rank:
  • GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
  • GF Score™: 17/100 with 7 warning signs

No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apontis Pharma AG Business Description

Address Rolf-Schwarz-Schutte-Platz 1, Monheim, BY, DEU, 40789
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score

Get the complete analysis for FRA:APPH

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.00
Price
€10.46
GF Value